CalciMedica Files Proxy Materials

Ticker: CALC · Form: DEFA14A · Filed: Apr 30, 2025 · CIK: 1534133

Calcimedica, INC. DEFA14A Filing Summary
FieldDetail
CompanyCalcimedica, INC. (CALC)
Form TypeDEFA14A
Filed DateApr 30, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-filing, corporate-governance

TL;DR

CalciMedica filed proxy docs, no fee. Looks like they're moving forward with shareholder stuff.

AI Summary

CalciMedica, Inc. filed a Definitive Additional Materials proxy statement on April 30, 2025. This filing relates to the company's proxy materials and does not involve a fee. The company, formerly known as Graybug Vision, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates that CalciMedica is proceeding with corporate actions requiring shareholder approval, which could impact the company's strategic direction and future operations.

Risk Assessment

Risk Level: low — This is a routine filing of proxy materials and does not contain information about significant financial events or strategic shifts that would inherently increase risk.

Key Players & Entities

FAQ

What is the purpose of this DEFA14A filing?

This filing is a Definitive Additional Materials proxy statement filed by CalciMedica, Inc. to provide information required in a proxy statement.

When was this filing made?

The filing was made on April 30, 2025.

Does this filing involve a fee?

No, the filing explicitly states 'No fee' is required.

What is CalciMedica, Inc.'s former name?

CalciMedica, Inc. was formerly known as Graybug Vision, Inc., with name changes occurring in 2017 and 2015.

What is CalciMedica's primary business sector?

CalciMedica, Inc. operates in the Pharmaceutical Preparations sector, with Standard Industrial Classification code 2834.

Filing Details

This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 30, 2025 regarding CalciMedica, Inc. (CALC).

View full filing on EDGAR

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing